Kim G Johnson

Associate Professor of Psychiatry and Behavioral Sciences · 2025 - Present Psychiatry & Behavioral Sciences, Adult Psychiatry & Psychology, Psychiatry & Behavioral Sciences

Division Chief, Memory Disorders in the Department of Neurology · 2019 - Present Neurology, Clinical Science Departments

Associate Professor in Neurology · 2025 - Present Neurology, Behavioral Neurology, Neurology

In the News

Published February 3, 2025

Assessing and Educating Patients About Mild Cognitive Impairment

Published January 22, 2025

Alzheimer's Clinic Provides Time and Hope

Published January 9, 2025

Dementia - Impact Not Just on Patients but on Families

View All News

Recent Publications

Recommended approaches to sharing individual research results in Alzheimer's disease research: A multidisciplinary expert Delphi consensus.

Journal Article J Alzheimers Dis · November 2025 BackgroundAs criteria for diagnosing Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) evolves, AD-related biological measures of biomarkers (e.g., amyloid, tau) and genetic status (e.g., APOE) have gained heightened value in research ... Full text Link to item Cite

Implementation of an Alzheimer's Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study.

Journal Article J Pers Med · October 1, 2025 Background/Objectives: A high-performing blood biomarker (BBM) test for Alzheimer's disease (AD) represents an accurate, accessible, and scalable tool to aid healthcare professionals (HCPs) evaluating patients presenting with signs or symptoms of mild cogn ... Full text Link to item Cite

Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.

Journal Article The Journal of Prevention of Alzheimer's Disease · August 2025 Full text Cite

View All Publications

Recent Grants

Long-term Follow-up to Evaluate the Safety of LX1001 in Participants with APOE4 Homozygote Alzheimer's Disease.

Clinical TrialPrincipal Investigator · Awarded by LEXEO Therapeutics, Inc · 2024 - 2029

A 6-month & 18-month prospective, randomized, placebo-controlled, double-blind dual clinical trial investigating efficacy and safety of buntanetap in treating participants of early Alzheimer's disea

Clinical TrialPrincipal Investigator · Awarded by Annovis Bio, Inc. · 2025 - 2028

Biopsy-based single cell assays for olfactory sensory changes in an Alzheimer's Disease cohort

ResearchCo Investigator · Awarded by National Institute on Aging · 2024 - 2028

View All Grants

Education, Training & Certifications

University of Pittsburgh, School of Medicine · 1999 M.D.